The Technical Advisory Group determined that the Covaxin vaccine met WHO standards for protection against COVID-19, and the benefits of the vaccine far outweighed the risks. In trials, Covaxin was found to be 78% effective against coronavirus 14 days or more after the second dose. One of its advantages is its simplicity in terms of storage, so this drug is well suited for poorer countries.
The drug is recommended to be administered in two doses at intervals of four weeks. So far, the drug has been approved for adults only. WHO admits that there is insufficient data to assess the efficacy and safety of this vaccine for pregnant women.
Context. In India, Covaxin was approved back in early January 2021. And in October, India was the first in the world to allow the use of a coronavirus vaccine for children aged 2 years or older. It was Covaxin that was approved.